Adult Transplant ICU, Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia
Bjoern-Ole Stueben
Department of General-, Visceral-, and Transplant Surgery, Medical Center University Duisburg-Essen, 45147 Essen, Germany
Dieter Peter Hoyer
Department of General-, Visceral-, and Transplant Surgery, Medical Center University Duisburg-Essen, 45147 Essen, Germany
Dieter Clemens Broering
Adult Transplant ICU, Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11211, Saudi Arabia
Dmitri Bezinover
Department of Anesthesiology and Critical Care 3400 Spruce Street, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
Since 1940 albumin has been used worldwide and is widely available commercially since this time. However, a meta-analysis in 1998 challenged the use of albumin and identified a trend toward higher mortality in critically ill patients who had received albumin. Since then, many studies including multicenter randomized controlled trials have been carried out investigating the safety and efficacy of albumin treatment in different patient cohorts. In this context, patient cohorts that benefit from albumin were identified. However, particularly in non-liver patients, the use of albumin remains controversial. In our comprehensive review, we would like to highlight the most important studies in the recent 20 years and therefore offer an evidence-based outlook for the use of albumin for patients treated in the ICU.
